SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or v...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/12/2064 |
| _version_ | 1827638051847798784 |
|---|---|
| author | Stephane Marot Djeneba Bocar Fofana Philippe Flandre Isabelle Malet Karen Zafilaza Valentin Leducq Diane Vivien Sarah Mrabet Corentin Poignon Vincent Calvez Laurence Morand-Joubert Anne-Geneviève Marcelin Joel Gozlan |
| author_facet | Stephane Marot Djeneba Bocar Fofana Philippe Flandre Isabelle Malet Karen Zafilaza Valentin Leducq Diane Vivien Sarah Mrabet Corentin Poignon Vincent Calvez Laurence Morand-Joubert Anne-Geneviève Marcelin Joel Gozlan |
| author_sort | Stephane Marot |
| collection | DOAJ |
| description | The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale. |
| first_indexed | 2024-03-09T16:11:13Z |
| format | Article |
| id | doaj.art-a2dd6ab3d45b497e95289911eb91ed07 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T16:11:13Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a2dd6ab3d45b497e95289911eb91ed072023-11-24T16:12:56ZengMDPI AGLife2075-17292022-12-011212206410.3390/life12122064SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization TestStephane Marot0Djeneba Bocar Fofana1Philippe Flandre2Isabelle Malet3Karen Zafilaza4Valentin Leducq5Diane Vivien6Sarah Mrabet7Corentin Poignon8Vincent Calvez9Laurence Morand-Joubert10Anne-Geneviève Marcelin11Joel Gozlan12Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceDepartment of Virology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, F-75013 Paris, FranceDepartment of Virology, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, F-75012 Paris, FranceDepartment of Virology, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), F-75012 Paris, FranceDepartment of Virology, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, F-75012 Paris, FranceThe SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale.https://www.mdpi.com/2075-1729/12/12/2064SARS-CoV-2COVID-19neutralizing antibodiesneutralization surrogate assaysSARS-CoV-2 variants |
| spellingShingle | Stephane Marot Djeneba Bocar Fofana Philippe Flandre Isabelle Malet Karen Zafilaza Valentin Leducq Diane Vivien Sarah Mrabet Corentin Poignon Vincent Calvez Laurence Morand-Joubert Anne-Geneviève Marcelin Joel Gozlan SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test Life SARS-CoV-2 COVID-19 neutralizing antibodies neutralization surrogate assays SARS-CoV-2 variants |
| title | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
| title_full | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
| title_fullStr | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
| title_full_unstemmed | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
| title_short | SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test |
| title_sort | sars cov 2 neutralizing responses in various populations at the time of sars cov 2 variant virus emergence evaluation of two surrogate neutralization assays in front of whole virus neutralization test |
| topic | SARS-CoV-2 COVID-19 neutralizing antibodies neutralization surrogate assays SARS-CoV-2 variants |
| url | https://www.mdpi.com/2075-1729/12/12/2064 |
| work_keys_str_mv | AT stephanemarot sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT djenebabocarfofana sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT philippeflandre sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT isabellemalet sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT karenzafilaza sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT valentinleducq sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT dianevivien sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT sarahmrabet sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT corentinpoignon sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT vincentcalvez sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT laurencemorandjoubert sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT annegenevievemarcelin sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest AT joelgozlan sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest |